The 'Ventus evo' is the 4th generation model ... To improve wet-road handling, Hankook has applied advanced drainage design technology to the tire grooves, enhancing both braking and stability ...

SEOUL, South Korea — South Korean tire makers Nexen Tire Corp., Kumho Tire Co. and Hankook Tire & Technology Co. recently won Green Good Design Sustainability Awards for their tires. Nexen and Kumho ...

Hankook Tire has introduced the iON evo AS SUV, a high-performance all-season tire engineered specifically for large electric SUVs, through its collaboration with Lucid Motors. Designed with next ...

But as we said, this car is fast on the road. With all-wheel drive, clawing out of a corner on 285- and 295-section width Hankook Ventus S1 Evo Z tires (front and rear, respectively), grip is in ...

WE have teamed up with Hankook, official sponsors of the UEFA Conference League, to give two lucky Sun readers and a guest each a trip of a lifetime to the UEFA Conference League Final in Wroclaw ...

I purchased four Hankook tires with a 70,000 mi warranty. I have 16,400 miles on them as of now. Maybe a drop less. I was just told that the rumbling and bouncing is due to flat spots on all four ...

Cooler temperatures set the stage for some blistering times Monday at the 129th running of the Boston Marathon. Kenya's Sharon Lokedi smashed the women's course record, covering the 26.2-mile ...

The 129th Boston Marathon will occur on April 21, with 30,000 runners from 128 countries and all 50 states. Live coverage will be on ESPN2 from 9 a.m. to 12:30 p.m. ET, with additional coverage on ...

Runners from 128 countries and all 50 states will be participating in the 129th Boston Marathon, including 80 from Vermont. They will start in Hopkinton for the 26.2-mile trip to Boston on Monday ...

Among the models are the VANGUARD, GAMING TRIO, INSPIRE, VENTUS, and SHADOW series, each offering various features for specific needs. The VANGUARD "Dragon" series is the highest-end model ...

Denmark's Novo Nordisk has agreed to pay $70 million to license rights to a drug developed by Ventus Therapeutics with potential in non-alcoholic steatohepatitis (NASH) and several other diseases ...